COAG
NASDAQ HealthcareHemab Therapeutics Holdings, Inc. - Common Stock
Biotechnology
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $44.53 |
|---|---|
| 成交量 | 392,330 |
| 市值 | 2.08B |
| RSI（14日） | 77.7 超买 |
| 50日均线 | $29.53 |
| 52周最高 | $45.27 |
| 52周最低 | $23.00 |
| Forward P/E | -17.72 |
| Price / Book | -0.21 |
🎯 投资策略评分
COAG 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (93/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 COAG in your text
粘贴任何文章、记录或帖子 — 工具将提取 COAG 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.